Evidence map›Paper›PMID 41483104›Full record

Trial reportJournal of neural transmission (Vienna, Austria : 1996)2026

Kynurenine metabolites unchanged after multinutrient supplementation in children with ADHD: a secondary data analysis from the MADDY study.

Alisha M Bruton, Hayleigh K Ast, Lydia Norby-Adams, Priya Srikanth, Lisa M Robinette, Irene E Hatsu, Brenda M Y Leung, L Eugene Arnold, David Zava, Jeanette M Johnstone

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alisha M BrutonCenter for Mental Health Innovation, Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA. BrutonA@ohsu.edu.ORCID http://orcid.org/0000-0002-5929-3149
Hayleigh K AstCenter for Mental Health Innovation, Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA.ORCID http://orcid.org/0000-0002-2521-0309
Lydia Norby-AdamsCenter for Mental Health Innovation, Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA.ORCID http://orcid.org/0009-0001-1248-8723
Priya SrikanthOregon Health & Science University-Portland State University School of Public Health, Portland, OR, USA.ORCID http://orcid.org/0000-0002-0906-6757
Lisa M RobinetteCenter for Biobehavioral Health, Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-9314-9538
Irene E HatsuDepartment of Human Sciences, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-0501-9088
Brenda M Y LeungFaculty of Health Sciences, University of Lethbridge, Lethbridge, AB, Canada.ORCID http://orcid.org/0000-0002-4699-8086
L Eugene ArnoldDepartment of Psychiatry & Behavioral Health, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-0886-0692
David ZavaZRT Laboratory, Beaverton, OR, USA.ORCID http://orcid.org/0000-0001-7558-8732
Jeanette M JohnstoneCenter for Mental Health Innovation, Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA.ORCID http://orcid.org/0000-0003-3947-5540

Funding

Calgary Foundation Calgary FoundationFoundation for Excellence in Mental Health Care Foundation for Excellence in Mental Health CareGratis Foundation Gratis Foundation
6 · The paper itself

Abstract

Attention-deficit/hyperactivity disorder (ADHD) affects up to 10% of children, often presenting with emotional dysregulation (irritability, anger). The kynurenine pathway, by which the amino acid tryptophan is converted into both neuroprotective and neurotoxic metabolites, was investigated for its role in ADHD pathophysiology. The MADDY study was an 8-week, multi-site, randomized controlled trial of a multinutrient supplement versus placebo in children 6-12 years old with symptoms of ADHD and emotional dysregulation. Participants from two U.S. sites (n = 84) provided baseline and week 8 urinary samples, analyzed via liquid chromatography-mass spectrometry for neurotransmitter levels. Linear mixed-effects models assessed change over time for seven analytes. Missing values were imputed, and results adjusted for multiple comparisons. Baseline neurotransmitter concentrations were not different between treatment groups. Changes over time in the seven analytes were not different between treatment groups. Nine participants had neurotransmitter levels below the lower limit of detection and were imputed; demographic characteristics were not different between these and other participants. Eight weeks of multinutrient supplementation did not change concentrations of urinary tryptophan, serotonin, or kynurenines in this sample of children 6-12 years old with ADHD and emotional dysregulation.

Indexed as

Attention Deficit Disorder with HyperactivityDietary SupplementsKynurenineChildChromatography, LiquidFemaleHumansMaleTryptophanKynurenineTryptophanADHDEmotion regulationInflammationIntegrative medicineKynurenineSerotonin

Identifiers

PMID41483104

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.